-
Exagamglogene autotemcel, sold
under the
brand name
Casgevy, is a gene
therapy used for the
treatment of
sickle cell
disease and transfusion-dependent...
-
Retrieved 4
December 2023. "Patient
Information |
CASGEVY® (exagamglogene autotemcel)". www.
casgevy.com.
Archived from the
original on 2
December 2024...
- therapy,
Casgevy, also
known as Exa-cel, is to be
offered to
patients on the
National Health Service (NHS) in
England as from 2025. Both
Casgevy and Lyfgenia...
-
CRISPR gene editing,
Casgevy, was
approved for use in the
United Kingdom, to cure sickle-cell
disease and beta thal****emia.
Casgevy was
approved for use...
- Agency.
Reproduction is
authorized provided the
source is acknowledged. "
Casgevy". U.S. Food and Drug
Administration (FDA). 8
December 2023.
Retrieved 8...
- have been developed.
Exagamglogene autotemcel, sold
under the
brand name
Casgevy, is a gene
therapy for the
treatment of transfusion-dependent beta thal****emia...
-
Vertex and
CRISPR Therapeutics that led to the
discovery and
development of
Casgevy, (exagamglogene autotemcel;
formerly known as CTX001), the
first gene editing...
-
therapy that
works through the CRISPR/Cas9 system. The
therapy known as
Casgevy works through editing a
dysfunctional protein that
interferes with creation...
- (Hemgenix): AAV-based
treatment for
hemophilia B
Exagamglogene autotemcel (
Casgevy):
treatment for
sickle cell disease. Gendicine:
treatment for head and...
-
predicted the
development of gene
therapy for
sickle cell disease,
namely Casgevy,
which was FDA
approved in 2023. Her 2024
performance at the HOSA international...
